Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsCareOregon Peginterferon Coverage | OpenPayer
    Ask Trek AI about this page
    CurrentCareOregonPolicy N/A

    Peginterferon alfa-2a Prior Authorization Guideline

    Customize your policy alerts

    Sign up for all careoregon policy alerts

    Know when careoregon releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Prior authorization and reauthorization criteria for peginterferon alfa-2a used for chronic hepatitis D and specified other uses, including chronic hepatitis B, chronic hepatitis C, essential thrombocythemia, and HIV/hepatitis B coinfection.

    Policy Summary
    PayerCareOregon
    PolicyPeginterferon alfa-2a Prior Authorization Guideline
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateOctober 1, 2026
    Next Review DateN/A
    Key ActionFor reauthorization, submit documentation of detectable serum HDV RNA within the last 6 months and a reduction in HDV RNA levels.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    12 monthsApproval length
    2Specialist prescriber types
    4Specified other uses
    6 monthsHDV RNA documentation recency

    Coverage Criteria

    Policy Summary
    PayerCareOregon
    PolicyPeginterferon alfa-2a Prior Authorization Guideline
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateOctober 1, 2026
    Next Review DateN/A
    Key ActionFor reauthorization, submit documentation of detectable serum HDV RNA within the last 6 months and a reduction in HDV RNA levels.
    SourceLink
    On This Page
    Coverage CriteriaProvider ActionsDefinitionsInitial Therapy CriteriaContinuation Criteria

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Initial therapy — chronic hepatitis D

    Covered for initial authorization when all of the following are met.

    Initial chronic hepatitis D authorization

    • Diagnosis: The patient has a diagnosis of chronic hepatitis D infection.
    • Prescriber or consultant

      • Gastroenterologist: Peginterferon alfa-2a is prescribed by or in consultation with a gastroenterologist.
      • Hepatologist: Peginterferon alfa-2a is prescribed by or in consultation with a hepatologist.

    Continuation therapy — chronic hepatitis D

    Reauthorization requires the following documented clinical information.

    Chronic hepatitis D reauthorization

    • Detectable HDV RNA: Medical record documentation shows detectable serum HDV RNA levels.Within the last 6 months
    • Treatment response: Medical record documentation shows a reduction in HDV RNA levels.

    Initial therapy — other uses

    Covered for initial authorization when peginterferon alfa-2a is being used for one of the following conditions.

    Other covered uses

    • Chronic hepatitis B: Peginterferon alfa-2a is being used for chronic hepatitis B.
    • Chronic hepatitis C: Peginterferon alfa-2a is being used for chronic hepatitis C.
    • Essential thrombocythemia: Peginterferon alfa-2a is being used for essential thrombocythemia.
    • HIV/hepatitis B coinfection: Peginterferon alfa-2a is being used for HIV/hepatitis B co-infection.

    Provider Actions

    Prior Authorization

    Initial Chronic Hepatitis D Authorization

    For initial authorization of peginterferon alfa-2a for chronic hepatitis D, document the diagnosis and ensure the medication is prescribed by, or provided in consultation with, a gastroenterologist or hepatologist.

    • Approval length: 12 months.
    • Diagnosis of chronic hepatitis D infection is required.
    • Prescriber or consultant must be a gastroenterologist or hepatologist.
    Documentation Required

    Chronic Hepatitis D Reauthorization

    For reauthorization, submit medical-record documentation supporting continued therapy, including detectable serum HDV RNA within the last 6 months and evidence of a reduction in HDV RNA levels.

    • Reauthorization approval length: 12 months.
    • Document detectable serum HDV RNA within the last 6 months.
    • Include documentation of reduction in HDV RNA levels.
    Prior Authorization

    Authorization for Other Uses

    Peginterferon alfa-2a requires prior authorization when used for other specified conditions. Document that the patient has one of the qualifying indications.

    • Chronic hepatitis B.
    • Chronic hepatitis C.
    • Essential thrombocythemia.
    • HIV/hepatitis B co-infection.
    • Approval length: 12 months.
    Documentation Required

    Submit Reauthorization Documentation

    Submit the chronic hepatitis D reauthorization records within the required timeframe so the plan can verify ongoing eligibility. The records must show detectable serum HDV RNA from within the preceding 6 months.

    • Submit medical-record documentation with the reauthorization request.
    • The detectable serum HDV RNA result must be from within the last 6 months.

    Definitions

    Chronic hepatitis D
    TermChronic hepatitis D
    DefinitionChronic hepatitis D infection
    Related therapyPeginterferon alfa-2a
    Detectable serum HDV RNA
    TermDetectable serum HDV RNA
    DefinitionHepatitis D virus RNA detected in serum
    Recency requirementWithin the preceding 6 months

    Initial Therapy Criteria

    Chronic hepatitis D initial authorization

    Initial authorization requires both a diagnosis of chronic hepatitis D infection and qualifying specialist involvement.

    • Diagnosis: The patient has a diagnosis of chronic hepatitis D infection.
    • Prescriber or consultant

      • Gastroenterologist: Peginterferon alfa-2a is prescribed by or in consultation with a gastroenterologist.
      • Hepatologist: Peginterferon alfa-2a is prescribed by or in consultation with a hepatologist.

    Other uses initial authorization

    Initial authorization is available when peginterferon alfa-2a is used for one of the following conditions.

    Qualifying use

    • Chronic hepatitis B: Peginterferon alfa-2a is being used for chronic hepatitis B.
    • Chronic hepatitis C: Peginterferon alfa-2a is being used for chronic hepatitis C.
    • Essential thrombocythemia: Peginterferon alfa-2a is being used for essential thrombocythemia.
    • HIV/hepatitis B coinfection: Peginterferon alfa-2a is being used for HIV/hepatitis B co-infection.

    Continuation Criteria

    Chronic hepatitis D reauthorization

    Reauthorization requires medical record documentation of both detectable serum HDV RNA and a reduction in HDV RNA levels.

    • Detectable serum HDV RNA: Medical record documentation shows detectable serum HDV RNA levels.Within the last 6 months
    • Reduction in HDV RNA: Medical record documentation shows a reduction in HDV RNA levels.